Circulating Tumor Cells Market Size Outlook and Demand Growth Across 2026–2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Circulating Tumor Cells Market Expected To Change Between 2026 And 2030?

The circulating tumor cells market has observed rapid expansion in its size over recent years. It is projected to expand from $13.27 billion in 2025 to $14.99 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. This historical expansion can be ascribed to several factors: increasing cancer incidence rates, the expansion of oncology research programs, the growing use of blood-based diagnostics, the rising adoption of minimally invasive testing methods, and the availability of advanced laboratory technologies.

The circulating tumor cells market size is expected to witness significant expansion in the coming years. It is projected to grow to **$23.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%**. This growth during the forecast period can be attributed to the rising adoption of personalized oncology diagnostics, increasing investments in cancer biomarker research, the expansion of automated cell capture technologies, a growing demand for early-stage cancer detection tools, and the increasing integration of artificial intelligence in oncology diagnostics. Key trends expected over the forecast period include the increasing use of liquid biopsy techniques, a rise in the adoption of microfluidic CTC isolation devices, the growing integration of automated CTC analysis systems, the expansion of oncology research applications, and an enhanced focus on early cancer detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8950&type=smp

What Underlying Factors Are Accelerating The Growth Of The Circulating Tumor Cells Market?

The increasing occurrence of cancer is projected to drive the expansion of the circulating tumor cells market in the future. Cancer is defined as a condition where certain body cells multiply without control and disseminate to various regions. Circulating tumor cells assist in the prompt identification and diagnosis of cancer; consequently, the rising prevalence of cancer fuels the development of the circulating tumor cells market. For example, data from February 2024, published by the World Health Organization – an international entity based in Switzerland focused on global health policy and public health efforts – indicates that more than 35 million new cancer cases are anticipated by 2050. This represents a 77% surge from the approximately 20 million cases recorded in 2022. As a result, the rising incidence of cancer is a key factor propelling the expansion of the circulating tumor cells market.

How Is The Circulating Tumor Cells Market Structured Across Different Segments?

The circulating tumor cells market covered in this report is segmented –

1) By Product: Kits And Reagents, Blood Collection Tubes, Devices Or Systems

2) By Technology: CTC Enrichment, CTC Detection, CTC Analysis

3) By Application: Clinical Or Liquid Biopsy, Research

Subsegments:

1) By Kits And Reagents: Cell Enrichment Kits, Detection Kits, Nucleic Acid Isolation Kits

2) By Blood Collection Tubes: Standard Blood Collection Tubes, Specialized Blood Collection Tubes

3) By Devices Or Systems: Microfluidic Devices, Automated Cell Capture Systems, Imaging Systems

Which Trends Are Shaping The Future Of The Circulating Tumor Cells Market?

Leading companies in the circulating tumor cells (CTC) market are concentrating on developing advanced solutions, such as biomarker-specific CTC assays, to address the increasing need for precise, non-invasive cancer diagnostics and sophisticated personalized therapy monitoring. Biomarker-specific CTC assays enable the identification and characterization of circulating tumor cells based on specific protein expression, yielding more comprehensive phenotypic data than traditional CTC enumeration methods, which primarily offer total cell counts without biomarker differentiation. For example, in July 2023, Menarini Silicon Biosystems S.p.A., an Italy-based diagnostics company, released the CELLSEARCH CTC test with the DLL3 biomarker, now accessible as a Research Use Only (RUO) service in North America and Europe. This assay utilizes the FDA-cleared CELLSEARCH platform to detect circulating tumor cells expressing DLL3, a protein that is overexpressed in aggressive small-cell lung cancer (SCLC) and neuroendocrine tumors. By focusing on DLL3, the test facilitates the phenotypic characterization of CTCs associated with poor prognosis, thereby supporting biopharma research in the development of targeted therapies. This innovation offers researchers a non-invasive instrument for studying tumor heterogeneity, monitoring disease progression, and assessing responses to targeted treatments.

Which Major Players Dominate The Circulating Tumor Cells Market?

Major companies operating in the circulating tumor cells market are BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., ScreenCell SAS, Aviva Biosciences Corporation, LungLife AI Inc., Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd., Bio-Techne Corporation, Qiagen N.V., STEMCELL Technologies Inc., Sysmex Corporation, Miltenyi Biotec GmbH, Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Agilent Technologies Inc.

Read the full circulating tumor cells market report here:

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Which Region Is Projected To Dominate The Circulating Tumor Cells Market During The Forecast Period?

North America was the largest region in the circulating tumor cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Circulating Tumor Cells Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8950&type=smp

Browse Through More Reports Similar to the Global Circulating Tumor Cells Market 2026, By The Business Research Company

Chronic Obstructive Pulmonary Disease Copd Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795